{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:02Z","timestamp":1786980482796,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10067-017-3671-0","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T03:27:47Z","timestamp":1494300467000},"page":"1919-1926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review"],"prefix":"10.1007","volume":"36","author":[{"given":"Roberta Vilela Lopes","family":"Koyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Kiyoshi Kitabayashi","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Alberto","family":"da Silva Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellen Thais","family":"Fuzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto Toshimitsu","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"3671_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jaut.2013.11.005","volume":"48-49","author":"L Iaccarino","year":"2014","unstructured":"Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L et al (2014) The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 48-49:122\u2013127. doi:\n10.1016\/j.jaut.2013.11.005","journal-title":"J Autoimmun"},{"issue":"12","key":"3671_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11926-014-0465-0","volume":"16","author":"E Bailey","year":"2014","unstructured":"Bailey E, Fiorentino D (2014) Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep 16(12):465. doi:\n10.1007\/s11926-014-0465-0","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"3671_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/CND.0000000000000038","volume":"15","author":"R Neri","year":"2014","unstructured":"Neri R, Barsotti S, Iacopetti V, Tripoli A, d\u2019Ascanio A, Tavoni AG et al (2014) Clinically amyopathic dermatomyositis: analysis of a monocentric cohort. J Clin Neuromuscul Dis 15(4):157\u2013160. doi:\n10.1097\/CND.0000000000000038","journal-title":"J Clin Neuromuscul Dis"},{"issue":"5","key":"3671_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1378\/chest.08-2740","volume":"136","author":"H Mukae","year":"2009","unstructured":"Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S et al (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136(5):1341\u20131347. doi:\n10.1378\/chest.08-2740","journal-title":"Chest"},{"issue":"4","key":"3671_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/14397595.2013.874762","volume":"24","author":"H Tsuchiya","year":"2014","unstructured":"Tsuchiya H, Tsuno H, Inoue M, Takahashi Y, Yamashita H, Kaneko H et al (2014) Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol 24(4):694\u2013696. doi:\n10.3109\/14397595.2013.874762","journal-title":"Mod Rheumatol"},{"issue":"8","key":"3671_CR6","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s10067-015-2928-8","volume":"35","author":"B Gil","year":"2016","unstructured":"Gil B, Merav L, Pnina L, Chagai G (2016) Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol 35(8):2125\u20132130. doi:\n10.1007\/s10067-015-2928-8","journal-title":"Clin Rheumatol"},{"issue":"10","key":"3671_CR7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","volume":"62","author":"P Morganroth","year":"2010","unstructured":"Morganroth P, Kreider M, Werth V (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res 62(10):1496\u20131501. doi:\n10.1002\/acr.20212","journal-title":"Arthritis Care Res"},{"issue":"10","key":"3671_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.annder.2013.04.083","volume":"140","author":"C Girard","year":"2013","unstructured":"Girard C, Vincent T, Bessis D (2013) Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case. Ann Dermatol Venereol 140(10):628\u2013634. doi:\n10.1016\/j.annder.2013.04.083","journal-title":"Ann Dermatol Venereol"},{"key":"3671_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40064-015-1013-8","volume":"4","author":"S Ikeda","year":"2015","unstructured":"Ikeda S, Arita M, Misaki K, Mishima S, Takaiwa T, Nishiyama A et al (2015) Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Spring 4:240. doi:\n10.1186\/s40064-015-1013-8","journal-title":"Spring"},{"issue":"8","key":"3671_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10067-009-1152-9","volume":"28","author":"H Cao","year":"2009","unstructured":"Cao H, Parikh TN, Zheng J (2009) Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol 28(8):979\u2013984. doi:\n10.1007\/s10067-009-1152-9","journal-title":"Clin Rheumatol"},{"issue":"5","key":"3671_CR11","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00296-012-2545-7","volume":"33","author":"Y Sun","year":"2013","unstructured":"Sun Y, Liu Y, Yan B, Shi G (2013) Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients. Rheumatol Int 33(5):1295\u20131302. doi:\n10.1007\/s00296-012-2545-7","journal-title":"Rheumatol Int"},{"issue":"4","key":"3671_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10067-009-1358-x","volume":"29","author":"M Ando","year":"2010","unstructured":"Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka R et al (2010) Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 29(4):443\u2013445. doi:\n10.1007\/s10067-009-1358-x","journal-title":"Clin Rheumatol"},{"issue":"6","key":"3671_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/BOR.0b013e32833f1970","volume":"22","author":"A Labirua","year":"2010","unstructured":"Labirua A, Lundberg IE (2010) Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 22(6):633\u2013638. doi:\n10.1097\/BOR.0b013e32833f1970","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"3671_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11926-012-0246-6","volume":"14","author":"T Mimori","year":"2012","unstructured":"Mimori T, Nakashima R, Hosono Y (2012) Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 14(3):264\u2013274. doi:\n10.1007\/s11926-012-0246-6","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"3671_CR15","first-page":"30","volume":"49","author":"K Nagata","year":"2011","unstructured":"Nagata K, Tomii K, Nanjo S, Kubota M, Tachikawa R, Nishio M (2011) Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody. The Journal of the Japanese Respiratory Society 49(1):30\u201336","journal-title":"The Journal of the Japanese Respiratory Society"},{"issue":"4","key":"3671_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10165-011-0558-9","volume":"22","author":"S Sato","year":"2011","unstructured":"Sato S, Kuwana M, Fujita T, Suzuki Y (2011) Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140\/MDA5 autoantibodies. Mod Rheumatol 22(4):625\u2013629. doi:\n10.1007\/s10165-011-0558-9","journal-title":"Mod Rheumatol"},{"issue":"1","key":"3671_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s10165-012-0637-6","volume":"23","author":"Y Horai","year":"2013","unstructured":"Horai Y, Isomoto E, Koga T, Okada A, Kawashiri S, Tamai M et al (2013) Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol 23(1):190\u2013194. doi:\n10.1007\/s10165-012-0637-6","journal-title":"Mod Rheumatol"},{"issue":"10","key":"3671_CR18","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","volume":"26","author":"S Ye","year":"2007","unstructured":"Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ et al (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26(10):1647\u20131654. doi:\n10.1007\/s10067-007-0562-9","journal-title":"Clin Rheumatol"},{"issue":"2","key":"3671_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/14397595.2013.852847","volume":"24","author":"H Ichiyasu","year":"2014","unstructured":"Ichiyasu H, Horio Y, Tsumura S, Hirosako S, Sakamoto Y, Sakata S et al (2014) Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three cases. Mod Rheumatol 24(2):361\u2013365. doi:\n10.3109\/14397595.2013.852847","journal-title":"Mod Rheumatol"},{"issue":"6","key":"3671_CR20","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1378\/chest.13-0186","volume":"144","author":"A Teruya","year":"2013","unstructured":"Teruya A, Kawamura K, Ichikado K, Sato S, Yasuda Y, Yoshioka M (2013) Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140\/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest 144(6):1934\u20131936. doi:\n10.1378\/chest.13-0186","journal-title":"Chest"},{"key":"3671_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/750275","author":"O Sasaki","year":"2013","unstructured":"Sasaki O, Dohi M, Harada H, Imamura M, Tsuchida Y, Yamaguchi K et al (2013) A case of polymyxin b-immobilized fiber column treatment for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis. Case Rep Med. doi:\n10.1155\/2013\/750275","journal-title":"Case Rep Med"},{"issue":"8","key":"3671_CR22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2169\/internalmedicine.47.0639","volume":"47","author":"T Kakugawa","year":"2008","unstructured":"Kakugawa T, Mukae H, Saito M, Ishii K, Ishimoto H, Sakamoto N et al (2008) Rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intern Med 47(8):785\u2013790. doi:\n10.2169\/internalmedicine.47.0639","journal-title":"Intern Med"},{"key":"3671_CR23","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1014140","author":"Y Koichi","year":"2015","unstructured":"Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M et al (2015) A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. doi:\n10.3109\/14397595.2015.1014140","journal-title":"Mod Rheumatol"},{"issue":"3","key":"3671_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3109\/14397595.2015.1012797","volume":"26","author":"R Watanabe","year":"2016","unstructured":"Watanabe R, Ishii T, Araki K, Ishizuka M, Kamogawa Y, Fujita Y et al (2016) Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol 26(3):465\u2013466. doi:\n10.3109\/14397595.2015.1012797","journal-title":"Mod Rheumatol"},{"issue":"8","key":"3671_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","volume":"73","author":"J Zou","year":"2014","unstructured":"Zou J, Li T, Huang X, Chen S, Guo Q, Bao C (2014) Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis 73(8):1591\u20131593. doi:\n10.1136\/annrheumdis-2014-205278","journal-title":"Ann Rheum Dis"},{"key":"3671_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep33226","author":"T Li","year":"2016","unstructured":"Li T, Guo L, Chen Z, Gu L, Sun F, Tan X et al (2016) Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. doi:\n10.1038\/srep33226","journal-title":"Sci Rep"},{"issue":"1","key":"3671_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12511","volume":"280","author":"CV Oddis","year":"2016","unstructured":"Oddis CV (2016) Update on the pharmacological treatment of adult myositis. J Intern Med 280(1):63\u201374. doi:\n10.1111\/joim.12511","journal-title":"J Intern Med"},{"issue":"1","key":"3671_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1378\/chest.130.1.30","volume":"130","author":"FJ Swigris","year":"2006","unstructured":"Swigris FJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK et al (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130(1):30\u201336. doi:\n10.1378\/chest.130.1.30","journal-title":"Chest"},{"issue":"11","key":"3671_CR29","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","volume":"30","author":"CP Sime\u00f3n-Aznar","year":"2011","unstructured":"Sime\u00f3n-Aznar CP, Fonollosa-Pl\u00e1 V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laqu\u00e9 R, Vilardell-Tarr\u00e9s M (2011) Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 30(11):1393\u20131398. doi:\n10.1007\/s10067-011-1823-1","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3671_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13075-016-1015-0","volume":"18","author":"PD Shenoy","year":"2016","unstructured":"Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S (2016) Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther 18(1):123. doi:\n10.1186\/s13075-016-1015-0","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"3671_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. doi:\n10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3671_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/BOR.0000000000000270","volume":"28","author":"B Wallace","year":"2016","unstructured":"Wallace B, Vummidi D, Khanna D (2016) Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol 28(3):236\u2013245. doi:\n10.1097\/BOR.0000000000000270","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"3671_CR33","first-page":"170","volume":"100","author":"C Owen","year":"2016","unstructured":"Owen C, Ngian GS, Elford K, Moore O, Stevens W, Nikpour M et al (2016) Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clin Exp Rheumatol 34 Suppl 100(5):170\u2013176","journal-title":"Clin Exp Rheumatol 34 Suppl"},{"issue":"15","key":"3671_CR34","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","volume":"168","author":"LA Saketkoo","year":"2008","unstructured":"Saketkoo LA, Espinoza LR (2008) Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 168(15):1718\u20131719. doi:\n10.1001\/archinte.168.15.1718","journal-title":"Arch Intern Med"},{"issue":"5","key":"3671_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","volume":"337","author":"LA Saketkoo","year":"2009","unstructured":"Saketkoo LA, Espinoza LR (2009) Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 337(5):329\u2013335. doi:\n10.1097\/MAJ.0b013e31818d094b","journal-title":"Am J Med Sci"},{"issue":"6","key":"3671_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1759720X15612250","volume":"7","author":"K Iqbal","year":"2015","unstructured":"Iqbal K, Kelly C (2015) Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis 7(6):247\u2013267. doi:\n10.1177\/1759720X15612250","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"3671_CR37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","volume":"107","author":"IC Mira-Avendano","year":"2013","unstructured":"Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT et al (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis. Respir Med 107(6):890\u2013896. doi:\n10.1016\/j.rmed.2013.02.015","journal-title":"Respir Med"},{"issue":"5","key":"3671_CR38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640\u2013646. doi:\n10.3899\/jrheum.121043","journal-title":"J Rheumatol"},{"issue":"9","key":"3671_CR39","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.rmr.2014.02.010","volume":"31","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Ahmad K, Piegay F, Fabien N, Raphanel B, Cordier JF et al (2014) Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies. Rev Mal Respir 31(9):849\u2013853. doi:\n10.1016\/j.rmr.2014.02.010","journal-title":"Rev Mal Respir"},{"issue":"6","key":"3671_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3109\/08923973.2013.833624","volume":"35","author":"E Cozzani","year":"2013","unstructured":"Cozzani E, Cinotti E, Felletti R, Pelucco D, Rebora A, Parodi A (2013) Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. Immunopharmacol Immunotoxicol 35(6):687\u2013692. doi:\n10.3109\/08923973.2013.833624","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"3671_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3443-2","author":"M Hayashi","year":"2017","unstructured":"Hayashi M, Kikuchi T, Takada T (2017) Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies. Clin Rheumatol. doi:\n10.1007\/s10067-016-3443-2","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3671-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3671-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3671-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T09:17:37Z","timestamp":1500542257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3671-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3671"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3671-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,9]]}}}